Crossmark

Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis

Crossref DOI link: https://doi.org/10.1007/s10147-021-02046-z

Published Online: 2021-10-11

Published Print: 2022-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Isobe, Teruki

Naiki, Taku https://orcid.org/0000-0002-7638-6048
Sugiyama, Yosuke

Naiki-Ito, Aya

Nagai, Takashi

Etani, Toshiki

Nozaki, Satoshi

Iida, Keitaro

Noda, Yusuke

Shimizu, Nobuhiko

Tomiyama, Nami

Banno, Rika

Kubota, Hiroki

Hamamoto, Shuzo

Ando, Ryosuke

Kawai, Noriyasu

Yasui, Takahiro
License Information

Text and Data Mining valid from 2021-10-11

Version of Record valid from 2021-10-11
More Information

Article History

Received: 30 July 2021

Accepted: 30 September 2021

First Online: 11 October 2021

Declarations

:

: The authors wish to declare that they have no conflicts of interest.

: The ethics committee of Nagoya City University Hospital approved this study (# 60-18-0060) to be performed in accordance with the Declaration of Helsinki (2013 Fortaleza). Ethical investigations were performed as certified by each author.

: Written informed consent was supplied by all patients.

Document is current

Any future updates will be listed below